According to the American Alzheimer's Association, said the existing U.S. 530 million Alzheimer's patients, spends 172 billion U.S. dollars, from 2002 to 2006, mortality rates of Alzheimer's disease increased by 46%.
The U.S. is developing Alzheimer's disease and related drugs are nearly 100 species, of which Alzheimer's disease treatment and prevention of drug 79 species, 18 kinds of cognitive diseases, drugs, dementia, 2 kinds of drugs, diagnosis of Alzheimer's disease Reagent 5.
This paper reviews the current field of Alzheimer's disease drugs market, R & D and testing of product failure, glue gun we may be able to Alzheimer's disease drug market from the current situation, with the help and experience of failure to explore the future trends.
Listed products: generic drugs are underway.
Galantamine (brand name: Razadyne, Nivalin)
Galantamine is a cholinesterase inhibitor for the treatment of mild to moderate Alzheimer's disease. Bulgaria's Sopharma initially by pharmaceutical companies in research and production, from the snow lotus bulbs separation and extraction, the current number of countries in the world market. Because the extraction of rare species,glue stick extract galantamine Minang expensive, many companies began to trigger a global way by chemical synthesis of synthetic galantamine, for example, Johnson & Johnson subsidiary Ortho-McNeil Pharmaceutical production and sales of Razadyne. Recently, India's largest drug maker Sun Pharmaceutical Co., Ltd. to obtain FDA approval of generic galantamine in the U.S.. Galantamine help in the limited time delay and prevention of Alzheimer's disease symptoms worsen.
Ellis's Ming (trade name: Exelon)
Exelon is a cholinesterase inhibitor developed by Novartis for the treatment of moderate dementia caused by Alzheimer's disease. There are many on the market today Aires Ming generic drugs, including Sandoz and Sun Pharmaceutical Co., Ltd. products. Alzheimer's disease is a major cause of chemical signals and memory-related decline in acetylcholine levels and cholinesterase inhibitors can increase the effects of acetylcholine. With the progress of Alzheimer's disease, brain acetylcholine produced by subsequent reduction, such as Ellis's Ming period of time in the use of drug efficacy will be greatly reduced.
Donepezil (brand name: Aricept)
According to the Mayo Clinic said that donepezil is a cholinesterase inhibitor prescription drugs can be the first once-daily drug use, and low incidence of serious side effects may be temporary delay of mild cognitive impairment (thought to be al- prodromal symptoms of Alzheimer's disease) to speed the development of Alzheimer's disease. On the market donepezil by the Japanese company Eisai and Pfizer jointly developed. FDA has accepted Japan's Eisai Aricept transdermal patch formulation of new drugs. Donepezil patent expired in 2010, Roxane, Apotex, and Aurobindo made a number of companies generic donepezil brief listing of new drug applications.